Search for other papers by Rachel D C A Diniz in
Google Scholar
PubMed
Search for other papers by Renata M Souza in
Google Scholar
PubMed
Search for other papers by Roberto Salvatori in
Google Scholar
PubMed
Search for other papers by Alex Franca in
Google Scholar
PubMed
Search for other papers by Elenilde Gomes-Santos in
Google Scholar
PubMed
Search for other papers by Thiago O Ferrão in
Google Scholar
PubMed
Search for other papers by Carla R P Oliveira in
Google Scholar
PubMed
Search for other papers by João A M Santana in
Google Scholar
PubMed
Search for other papers by Francisco A Pereira in
Google Scholar
PubMed
Search for other papers by Rita A A Barbosa in
Google Scholar
PubMed
Search for other papers by Anita H O Souza in
Google Scholar
PubMed
Search for other papers by Rossana M C Pereira in
Google Scholar
PubMed
Search for other papers by Alécia A Oliveira-Santos in
Google Scholar
PubMed
Search for other papers by Allysson M P Silva in
Google Scholar
PubMed
Search for other papers by Francisco J Santana-Júnior in
Google Scholar
PubMed
Search for other papers by Eugênia H O Valença in
Google Scholar
PubMed
Search for other papers by Viviane C Campos in
Google Scholar
PubMed
Search for other papers by Manuel H Aguiar-Oliveira in
Google Scholar
PubMed
dwarfs). Interestingly, because the presence of NAFLD was found not to correlate with age, sex, degree of obesity, blood lipids, HOMA-IR, and therapy by statins or IGF1, the data were reported by Prof. Laron to be ‘not fitting with present theories of the
Search for other papers by Xia Wu in
Google Scholar
PubMed
Search for other papers by Zhiling Li in
Google Scholar
PubMed
Search for other papers by Wenjiang Sun in
Google Scholar
PubMed
Search for other papers by Huan Zheng in
Google Scholar
PubMed
.001 Aspirin ( n ,%) 6 (17.1%) 10 (11.2%) 0.017 Statins ( n ,%) 13 (37.1%) 18 (20.2%) 0.002 Metformin ( n ,%) 10 (28.6%) 20 (22.5%) 0.143 Sulfonylureas ( n ,%) 4 (11.4%) 4 (4.5%) 0.007 Oral contraceptives ( n
Search for other papers by Melinda Kertész in
Google Scholar
PubMed
Search for other papers by Szilárd Kun in
Google Scholar
PubMed
Search for other papers by Eszter Sélley in
Google Scholar
PubMed
Search for other papers by Zsuzsanna Nagy in
Google Scholar
PubMed
Search for other papers by Tamás Kőszegi in
Google Scholar
PubMed
Search for other papers by István Wittmann in
Google Scholar
PubMed
(mmHg) 77 ± 9 Heart rate (b.p.m) 75 ± 10 Drug therapy Antihypertensives ACE inhibitors (%) 14 (67) Calcium channel blockers (%) 9 (43) Diuretics (%) 7 (33) Statin (%) 6 (29
Search for other papers by Ram P Narayanan in
Google Scholar
PubMed
Search for other papers by Bo Fu in
Google Scholar
PubMed
Search for other papers by Adrian H Heald in
Google Scholar
PubMed
Search for other papers by Kirk W Siddals in
Google Scholar
PubMed
Search for other papers by Robert L Oliver in
Google Scholar
PubMed
Search for other papers by Julie E Hudson in
Google Scholar
PubMed
Search for other papers by Antony Payton in
Google Scholar
PubMed
Search for other papers by Simon G Anderson in
Google Scholar
PubMed
Search for other papers by Anne White in
Google Scholar
PubMed
Vascular Research Group, School of Community Based Medicine, Centre for Integrated Genomic Medical Research, Cardiovascular Research Group, Endocrinology and Diabetes, Salford R&D, Department of Endocrinology and Diabetes, Faculty of Medical, Human and Life Sciences, The University of Manchester, Manchester M13 9PT, UK
Search for other papers by William E R Ollier in
Google Scholar
PubMed
Vascular Research Group, School of Community Based Medicine, Centre for Integrated Genomic Medical Research, Cardiovascular Research Group, Endocrinology and Diabetes, Salford R&D, Department of Endocrinology and Diabetes, Faculty of Medical, Human and Life Sciences, The University of Manchester, Manchester M13 9PT, UK
Search for other papers by J Martin Gibson in
Google Scholar
PubMed
–2009) Percentage of subjects on sulphonylureas 36 (in 2002) 61 (2002–2009) Percentage of subjects on insulin 29.5 (in 2002) 43.3 (2002–2009) Percentage of subjects on statins 59 (in 2002) 85.5 (2002–2009) eGFR, estimated glomerular filtration rate by the
Search for other papers by L E Zijlstra in
Google Scholar
PubMed
Search for other papers by D M van Velzen in
Google Scholar
PubMed
Search for other papers by S Simsek in
Google Scholar
PubMed
Search for other papers by S P Mooijaart in
Google Scholar
PubMed
Department of Internal Medicine, HagaHospital, The Hague, The Netherlands
Search for other papers by M van Buren in
Google Scholar
PubMed
Search for other papers by D J Stott in
Google Scholar
PubMed
Search for other papers by I Ford in
Google Scholar
PubMed
Search for other papers by J W Jukema in
Google Scholar
PubMed
Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by S Trompet in
Google Scholar
PubMed
. Materials and methods All subjects were participants of the ‘PROspective study of Pravastatin in the Elderly at Risk’ (PROSPER), a double-blind, randomized, placebo-controlled trial, designed to investigate the relationship between statin treatment and the
Centre for Biological Timing, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
Search for other papers by Robert Maidstone in
Google Scholar
PubMed
Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester, UK
Search for other papers by Martin K Rutter in
Google Scholar
PubMed
Oxford Liver Unit, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, UK
Search for other papers by Thomas Marjot in
Google Scholar
PubMed
NIHR Oxford Health Biomedical Research Centre, and NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK
Search for other papers by David W Ray in
Google Scholar
PubMed
NIHR Oxford Health Biomedical Research Centre, and NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK
Search for other papers by Matthew Baxter in
Google Scholar
PubMed
fat metabolism is perturbed by shift work is an obvious and essential step. In addition, drugs targeting the liver may have differential effects depending on the time of day of administration. For example, statin drugs work best at night, and
Search for other papers by Shilpa Lingaiah in
Google Scholar
PubMed
Search for other papers by Laure Morin-Papunen in
Google Scholar
PubMed
Search for other papers by Terhi Piltonen in
Google Scholar
PubMed
Search for other papers by Inger Sundström-Poromaa in
Google Scholar
PubMed
Search for other papers by Elisabet Stener-Victorin in
Google Scholar
PubMed
Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for other papers by Juha S Tapanainen in
Google Scholar
PubMed
1492 – 1500 . ( https://doi.org/10.1210/jc.2011-3061 ) 10.1210/jc.2011-3061 24 Puurunen J Piltonen T Puukka K Ruokonen A Savolainen MJ Bloigu R Morin-Papunen L Tapanainen JS. Statin therapy worsens insulin sensitivity in women with polycystic ovary
Search for other papers by Andrea V Haas in
Google Scholar
PubMed
Search for other papers by Paul N Hopkins in
Google Scholar
PubMed
Search for other papers by Nancy J Brown in
Google Scholar
PubMed
Search for other papers by Luminita H Pojoga in
Google Scholar
PubMed
Search for other papers by Jonathan S Williams in
Google Scholar
PubMed
Search for other papers by Gail K Adler in
Google Scholar
PubMed
Search for other papers by Gordon H Williams in
Google Scholar
PubMed
± 13 −3 0.09 LDL (mg/dL) 114 ± 35 128 ± 36 14 <0.001 TG (mg/dL) 143 ± 101 143 ± 98 0 0.98 Statin use (%) 5.8 8.1 2.3 0.52 Current smoker (%) 10.4 9.0 −1.4 0.62 Values are
Department of Clinical Research, University of Basel Hospital, Basel, Switzerland
Search for other papers by Fahim Ebrahimi in
Google Scholar
PubMed
Department of Clinical Research, University of Basel Hospital, Basel, Switzerland
Search for other papers by Sandrine A Urwyler in
Google Scholar
PubMed
Division of Endocrinology, Diabetes and Metabolism, University Department of Medicine, Kantonsspital Aarau, Aarau, Switzerland
Search for other papers by Philipp Schuetz in
Google Scholar
PubMed
Division of Endocrinology, Diabetes and Metabolism, University Department of Medicine, Kantonsspital Aarau, Aarau, Switzerland
Search for other papers by Beat Mueller in
Google Scholar
PubMed
Search for other papers by Luca Bernasconi in
Google Scholar
PubMed
Search for other papers by Peter Neyer in
Google Scholar
PubMed
Department of Clinical Research, University of Basel Hospital, Basel, Switzerland
Search for other papers by Marc Y Donath in
Google Scholar
PubMed
Department of Clinical Research, University of Basel Hospital, Basel, Switzerland
Search for other papers by Mirjam Christ-Crain in
Google Scholar
PubMed
30/47 14/21 16/26 Dyslipidemia 57/67 29/34 28/33 Statin treatment 18/57 7/29 11/28 Obstructive sleep apnea 21/67 7/34 14/33 CPAP treatment 14/21 5/7 9/14 Smoking status
Search for other papers by Jothydev Kesavadev in
Google Scholar
PubMed
Search for other papers by Pradeep Babu Sadasivan Pillai in
Google Scholar
PubMed
Search for other papers by Arun Shankar in
Google Scholar
PubMed
Search for other papers by Gopika Krishnan in
Google Scholar
PubMed
Search for other papers by Sunitha Jothydev in
Google Scholar
PubMed
reveal the treatment allocation. Figure 1 Study flow diagram. During the run-in period, compliance to optimal diet, exercise, treatment with insulin and metformin (≥1000 mg), and stable treatment with statin and antihypertensives were